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Abstract
Background: Distress in patients with cancer influences their quality of life. Worldwide, screening on distress with
the Distress Thermometer (DT) in patients with cancer is recommended. However, the effects of the use of the DT
on the psychosocial wellbeing of the patient are unknown. A study to assess the psychosocial consequences of the
systematic use of the DT and its discussion by a nurse as compared to the usual care provided to outpatients who
are treated for primary breast cancer is needed.
Methods/design: The effectiveness of a nurse-led intervention with the DT will be tested in a non-blinded
randomized controlled trial. Patients treated with curative intent for breast cancer will be recruited from the
Radboud University Medical Center. The intervention consists of the DT together with discussion of the results
with the patient by a trained oncology nurse added to the usual care. Patients will be randomly allocated (1:1)
to either receive usual care or the usual care plus the intervention. Primary outcome measure is global quality
of life measured with the EORTC QLQ-C30. The functional and symptom scales of the EORTC QLQ-C30 and BR23,
Hospital Anxiety and Depression Scale, Impact of Event Scale, Illness Cognition Questionnaire and DT (baseline
and final measurement only) will be used to measure secondary outcomes. Questionnaires are obtained in both
arms at baseline, after completion of each type of cancer treatment modality and during follow up, with a three
and six months’ interval during the first and second year respectively.
Discussion: This study will be the first randomized controlled longitudinal study about the effectiveness of the
DT as nurse led-intervention. In case of proven effectiveness, future implementation and standardization of use
of the DT as part of routine care will be recommended.
Trial registration: This study is registered at clinicaltrial.gov march 17, 2010 (NCT01091584).
Keywords: Distress, Distress thermometer, Breast cancer, Quality of life, RCT, Nurse-led intervention, Nurse,
Oncology nurse, Screening, Psychosocial care
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Background
With an incidence of more than 1.67 million women
yearly, breast cancer is the second most frequently oc-
curring type of all cancers in the world [1]. Despite the
reported increase in survival rate, the diagnosis breast
cancer has a serious impact on a woman’s life [2, 3].
The National Comprehensive Cancer Network (NCCN)
summarizes the problems that patients with cancer
may encounter with the word“distress” and defines it as
‘a multifactorial unpleasant emotional experience of a
psychological (cognitive, behavioral, emotional), social
and/or spiritual nature that may interfere with the abil-
ity to cope effectively with cancer, its physical symptoms
and its treatment. Distress extends along a continuum
ranging from common normal feelings of vulnerability,
sadness and fears to problems that can become disab-
ling such as depression, anxiety, panic, social isolation
and existential and spiritual crisis’[4]. When patients
experience distress it impinges on their quality of life
and the time for recovery during and after treatment
[5–10]. The current NCCN guideline describes that 20-
47 % of patients with newly diagnosed and recurrent
cancer experience a significant level of distress [4].
Offering basic psychosocial care is a core task for physi-
cians and nurses. Psychosocial care could consist of edu-
cation about the disease and treatment process, emotional
support, as well as support in choosing treatment mo-
dalities. For optimal support, it is important to screen
for levels of distress and the unmet needs of the patient
[11, 12].
Screening for distress
The Distress Thermometer (DT) has become a worldwide
standard screening tool for distress in cancer patients
[4, 9, 10, 13–20] that facilitates a systematic approach
to distress detection. It consists of a VAS score and a
problem list. Without a systematic distress assessment
patients are at risk of under diagnosis and treatment
[4]. Its use can assist in the timely detection of distress
and facilitate early intervention. A screening instrument
like the DT provides guidance for discussions with pa-
tients. Its use gives attention and focus to psychosocial
issues, an increased awareness of distress and more effect-
ive communication between healthcare professionals and
patients [4].
Recently, an increasing number of papers have been
published on the validity of the DT in different languages
and on different cut-off points [4, 14–18, 21]. Additionally,
the DT is used in studies to measure distress related to
various tumor types [19, 20] and at different time points
during treatment and follow-up [9, 10, 22, 23]. Studies
about the effectiveness of the utilization of the DT are
scarce. Based on current knowledge, only one study
described a non-blinded randomized controlled trial about
the DT in comparison to standard care [24]. In this study
the DT was assessed once at baseline and patients filled
out questionnaires at 1, 6 and 12 months of follow up. No
effect on costs and no significant improvement on the
mood states among patients were found [24]. Due to this
lack of evidence on effectiveness there is an ongoing
discussion about the use of the DT [25–27].
Internationally, it is recommended to implement
guidelines to address psychosocial care, with for example
the DT, to manage the psychosocial impact of cancer as
part of daily oncology care [4, 28, 29].
However, it is still unconfirmed that systematic
screening with the DT and a subsequent discussion of
the results will lead to improved patients’ quality of life.
It is striking that the use of the DT is implemented as
standard care worldwide without any evidence of effect-
iveness. We therefore decided to investigate the added
value of using the DT systematic to improve their quality
of life by a nurse in oncology care in a randomized con-
trolled trial, in patients diagnosed with breast cancer.
The decision to focus on patients with breast cancer
was made for the following reasons; (1) breast cancer
has a high incidence, (2) most patients undergo a long
treatment process and (3) patients have high survival
rates. The high survival rate is essential to be able to
measure the effects of the intervention in preventing
long-term psychosocial problems.
Objective
The primary objective of this randomized controlled trial
is to evaluate the effect of a nurse-led DT intervention on
improving the quality of life of patients with breast cancer
who are treated with curative intent, compared to usual
care, after approximately two years of follow-up.
Methods
This study will be reported in accordance with the
SPIRIT guidelines [30].
Study design
The design of the study (also called Nurse Intervention
Project) is a non-blinded randomized controlled trial
(Fig. 1). In the intervention group, a thorough assess-
ment using the DT and a discussion of the results by a
trained oncology nurse will be added to the usual care.
Actions based on the outcomes of the DT will be taken
as necessary. The control group will receive the usual
care without using the DT. By comparing the results of
the intervention group with the control group the effect
of the intervention can be determined.
Participants eligibility
Inclusion criteria: women with histology proven malignancy
of the breast; who will receive treatment with curative
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intent, written and oral fluency in the Dutch language and
aged ≥ 18 years.
Exclusion criteria: men, women who have been treated
previously for a malignancy (except adequately treated
cervix carcinoma in situ and basal cell carcinoma of the
skin); women with psychiatric problems that impair
adherence to this study.
Recruitment
Patients will be recruited from the population of newly di-
agnosed breast cancer patients at the Radboud University
Medical Center. Women who have been diagnosed with
breast cancer and meet the inclusion criteria, will be
asked to participate in this study. The patients will be
monitored after surgery, during adjuvant treatment and
approximately two years during the follow up. Immedi-
ately following diagnosis participants will be verbally
briefed by a clinical nurse specialist about the study
and given an information pack containing a detailed in-
formation sheet and letter of invite to participate in the
study. This timing is crucial as it is preferable to collect
baseline measurement before start of the first treatment
modality. Following receipt of the information package
the patient has several days to consider participation in
the study. If the patient gives consent for further discus-
sion about the study, the investigator will then be in con-
tact with the patient by telephone or during the next
hospital visit to discuss further potential participation. In
the time frame between the diagnosis and the start of
treatment, the patient usually visits the responsible health-
care professional (surgeon, clinical nurse specialist or
oncologist). On that day, if appropriate, the patient will be
asked to confirm her participation and baseline measure-
ments will be taken in the hospital or at home. There are
paper-and-pencil and electronic versions of the assess-
ment available. Electronic completion reduces the risk of
Diagnosis Recruitment
Baseline (T0)
No Hormonal Therapy
Stratification
Hormonal Therapy
Final measure (T9)
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ControlIntervention
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T7: Q + DT
T8: Q + DT T8: Q
Fig. 1 Flow-chart of the nurse intervention project. Q: Questionnaires, DT: Distress Thermometer Intervention includes a thorough assessment
using the DT and a discussion of the results by a trained oncology nurse. The questionnaires are: EORTC QLQ-C30 = European Organization for Re-
search and Treatment of Cancer, Quality of Life Questionnaire; QLQ-BR23 = Quality of life- Breast Cancer; HADS = Hospital Anxiety and Depression
Scale; IES = Impact of Event Scale; ICQ = Illness Cognition Questionnaire; EQ-6D = EuroQol-6D and a diary
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missing data because the patient has to answer each ques-
tions before sending. A paper-and-pencil version of the
questionnaires will be available for those who are not
capable of filling it out electronically.
Randomization
The expectation is that approximately 75 % of the pa-
tients will receive hormonal therapy. Since mood
swings and fatigue are known side effects of hormonal
therapy [31], we will stratify for hormonal treatment.
We therefore will use a randomized block design, pre-
pared by an independent statistician. The patients will
be randomized in a 1:1 ratio, immediately after assess-
ment of the adjuvant treatment plan, which includes
the use of adjuvant hormonal therapy. Random assign-
ment using sequentially numbering will be done by a
physician not involved in the study. The result of the
randomization will be communicated by e-mail or mail
to the patient by the investigator.
Intervention
The intervention comprises of support by the trained
oncology nurse based on the discussion of the DT in
accordance to the protocol for assessing the need for
psychosocial care for cancer patients [13]. The inter-
vention is combined with the (follow up) visit to the
outpatient clinic.
The DT consists of a thermometer ranging from 0
(no distress) to 10 (extreme distress). In addition the
tool contains 47 questions (yes / no answers) related to
different issues. The issues have been categorized into:
practical issues, family / social issues, emotional issues,
religious / spiritual issues, physical issues. The DT con-
cludes with the question: “Would you like to talk with a
professional about your problems?” (yes/no/maybe). The
cut-off point is 5 [14].
The following steps will be made for each screening
moment with the DT:
1. The patient will receive an e-mail or mail about the
appointment with the trained oncology nurse, which
will take place in combination with regular visits in
the outpatient clinic.
2. The patient will fill out out the DT in the outpatient
clinic a few minutes before the appointment.
3. The trained oncology nurse will discuss the DT with
the patient before or after the visit with the
attending healthcare professional. The nurse will ask
on which problems the DT score is based and the
mentioned problems on the problem list will be
discussed. If the patient reports a lot of problems,
the nurse will ask the patient to prioritize the
problems indicated. At the end, the nurse will ask if
the patient would like to be referred to a
professional.
4. Time allocated to these meetings will last between 5
– 30 min, depending on the severity of the distress
and the nature of the problems.
5. If the patient reports a DT score of <5 the trained
oncology nurse will inquire whether the patient is
sufficiently in control of her situation. The low
distress score and the issues marked on the problem
list are discussed briefly. At a score ≥ 5 on the DT, an
extensive exploratory conversation between the nurse
and the patient will take place. The outcome of this
conversation will be discussed in a psychosocial Multi
Disciplinary Team (MDT). The MDT has been
established to discuss all patients of the intervention
group with a score of ≥ 5 on the DT and to discuss
patients who personally request additional support.
The participants of the MDT are the attending
healthcare professional and/or oncologist, the
trained oncology nurse, a social worker and clinical
psychologists. During the MDT a treatment plan is
composed when needed. The nurse will propose
this plan to the patient by phone.
Three oncology nurses will be trained by a clinical
psychologist to perform the intervention over three ses-
sions. A specific manual will be developed during the
training sessions and the intervention. In order to apply
consistency in the content and the discussion of the DT
with the patients, those three nurses will receive the
same training. They should be qualified as a nurse and
be knowledgeable in the course and treatment of breast
cancer. For financial reasons an independent trained
study nurse cannot be hired for this study. Because
oncology nurses from the wards have a high risk of con-
tamination the intervention group while being in contact
with patients from both the intervention and the control
group, they are not suited to deliver the intervention
themselves. Therefore, we will select three oncology
nurses who are not bedside nurses and are involved in
other than breast cancer patient groups on the out-
patient clinic. In order to build a trustworthy relation-
ship and give continuity to the care whenever possibly
the patient will meet the same oncology nurse at every
visit. During this study the DT is not implemented in
daily care so the oncology nurses of the departments
involved in the study will not use it in daily practice.
A short standard report (as incorporated in the manual)
will be filled out after each conversation. To prevent
contamination with other professionals, the report of the
conversation will not be included in the medical record of
the patient. The investigator of the study is also one of the
trained oncology nurses who will deliver the interventions.
In order to minimize the influence of the investigator on
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the results of the study, an independent database will be
created and an independent statistician will analyze the
data.
Usual care
As already mentioned, the DT will not be implemented in
daily care for patients with breast cancer during this study
period, therefore no professionals taking care of breast
cancer patients will use the DT. The usual care consists of
routine follow-up visits with the attending healthcare pro-
fessional (physician or clinical nurse specialist) according
to the Dutch breast cancer guideline [32] (see also meas-
uring time-points). Depending on the judgment of the re-
sponsible health care professional, the patients may be
referred to other health care professionals, if indicated. No
psychosocial MDT is available in usual care.
Measuring time-points
The baseline measurement will take place preferably
before breast surgery or start of the neo-adjuvant chemo-
therapy. During the first year of treatment the assessments
will take place at the end of each treatment modality. In
the second and third year, the follow-up visits will be in
line with the recommendations of the Dutch Breast
Cancer guideline [32]. This means that data will be col-
lected approximately every 3 months during the first and
every 6 months in the second year after the completion of
adjuvant treatment (except for trastuzumab or hormonal
therapy). This will result in a total of 8 – 10 measure-
ments, depending on the number of adjuvant therapies
(see Fig. 1). In order to monitor the effects of treatment
on the patients’ well-being in both the short- and long-
term, patients will be followed for two years after comple-
tion of the primary (adjuvant) treatment.
At all measuring time-points both groups will receive
questionnaires. The DT is included for both groups at
baseline and at the end of the study. At those time-points
the results will not be discussed with the patients.
Approximately two days before the regular visit to the at-
tending healthcare professional, the patient will be asked
to fill out the questionnaire electronically (Radquest soft-
ware, department of Medical Psychology) or on paper in
the hospital or at home. It takes 10–30 min to fill out the
questionnaires. Additionally, a diary will be provided to
the patient in which the consumed care and work absence
has to be noted and recorded. At the moment the patient
hands in the diary, a new one is provided by mail or per-
sonally. In case of non-response, a reminder will be send
within 2 weeks by e-mail or mail.
Study outcome measures
Demographic data and the use of psychosocial care are
measured with general questionnaires. Medical disease-
specific data will be collected from the electronic medical
record. A checklist will be used to collect the relevant
medical records from the patient’s status.
Primary outcome measure
The primary outcome will be the global quality of life
subscale as defined by the European Organization for
Research and Treatment of Cancer, Quality of Life
Questionnaire- C30 (EORTC QLQ C-30) [33]. The items
of the global health and global quality of life scale use a 7-
point linear analogue scale (very poor to excellent) [34].
Secondary outcomes
The secondary outcomes will be: breast cancer related
quality of life, anxiety, depression, emotional distress,
coping, illness cognitions and distress (Table 1).
Functional and symptom scales of the EORTC QLQ
C30 will be used to assess the other dimensions of
quality of life (see Table 1). Higher scores on the global
and function scales implies good quality of life. On the
symptom scales, low scores indicates less intense symp-
toms hence higher quality of life [33-35].
Breast cancer related quality of life will be assessed
with the breast cancer related questionnaire EORTC-
BR23 which consists of 23 questions and complements
the C30 [36].
Anxiety, depression and emotional distress will be
measured with the Hospital Anxiety and Depression
Scale (HADS). The HADS has two subscales (anxiety
and depression) and a total score of emotional distress.
The questionnaire consists of 14 questions with scores
ranging from 0 (not at all) to 3 (very much) [37–39].
The presence of coping problems will be measured
with Impact of Event Scale (IES). This questionnaire
provides an inventory of the effects of a shocking event
and focuses on the person’s feelings and thoughts over
the previous seven days. The IES has two subscales: in-
trusion and avoidance. The scores range from ‘not at all’,
‘rarely’, ‘sometimes’ and ‘often’[40].
To identify the role of illness cognitions in relation to
the treatment effectiveness we will use the Illness Cogni-
tion Questionnaire (ICQ). There are three subscales:
helplessness, acceptance and perceived benefits. The
scores range from 1 (none) to 4 (entirely) [41].
Distress will also be measured with the DT at baseline
and final measurement for both groups (see Fig. 1) [14].
In case we will find differences between both groups
on quality of life we will further explore the health care
utilization. These data will be gathered with a diary that
the patients will take home between measurement time-
points. Patients will register their health care utilization,
cancer-related absence from work, specific medication
and care. Quality of Life in relation to economic evalua-
tions will be measured using the EuroQol-6D (EQ-6D).
The EQ-6D comprises both the EQ-5D and an additional
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dimension namely, cognition. The EQ-5D measures
health on five dimensions (mobility, self-care, usual
activities, pain/discomfort, anxiety/depression). Every
dimension is differentiated in three levels: no problems,
some problems, and extreme problems. The EuroQol
Visual Analogue Scale (EQ-VAS) will also be used. The
EQ-VAS provides a subjective assessment of quality of
life on a scale ranging from 0 (worst health) to 100
(best health) [42].
Evaluation
At the end of the study, patients will be asked to evaluate
their experiences during the study period. In addition, the
intervention group will be asked to evaluate their experi-
ence of the intervention. The control group will be asked
about their need for more psychosocial support during
treatment or follow up.
Data management
We expect most patients will fill out the questionnaires
electronically. The results of the questionnaires will be
converted to SPSS by a data manager. Only the investi-
gators have access to the coding, storage of all ques-
tionnaires and the final dataset. The paper and pencil
questionnaires and medical characteristics will be en-
tered in the SPSS database by a research assistant. For
Table 1 Measurements and time points of the nurse intervention project
Questionnaires Target T0 T1-T8 T9 Response format
Demographic & medical characteristics Descriptive of the population X X X Multiple answers
EORTC QLQ-C30 Functional scales: physical, role, emotional, social, and
cognitive functioning (15 items)
X X X 4 point Likert scale
Range 15–60
Symptom scales: fatigue, pain, nausea/vomiting (7 items) X X X Range 7–28
Single symptom items (6 items) X X X Range 6–24
Global Health and global quality of life* (2 items) X X X 7 point linear analogue scale
Range 2–14
EORTC QLQ- BR23 Functional scales: body image, sexual functioning,
sexual enjoyment, future perspective (8 items)
X X X 4 point Likert scale
Range 8–32
Symptoms scales: arm symptoms, breast symptoms,
systemic therapy side effects, upset by hair loss (15 items)
X X X Range 15-60
DT General distress X X1 X 11 point visual analogue
Scale: range 0–10
Problem list (47 items) X X1 X Yes/no
Question: wish for referral (1 item) X X1 X Yes/no/maybe
HADS Emotional distress (14 items)
Subscales:
Anxiety (7 items)
Depression (7 items)
X X X 4 point Likert scale
Range 0–42 (total scale)
Range 0–21
Range 0-21
IES Coping with the cancer (15 items)
Subscales:
Intrusion (7 items)
Avoidance (8 items)
X X X 4 point scale
Range 0–75 (total score)
Range 0–35
Range 0-40
ICQ Illness perceptions (18 items)
Subscales:
Helplessness (6 items)
Acceptance (6 items)
Perceived benefits (6 items)
X X X 4 point Likert scale
Range 6–24
Range 6–24
Range 6-24
Diary Health care use and work absence X X Yes/no, frequency and reason
EQ-6D Quality of life in relation to economic evaluations (1 item) X X X Visual Analogue
Scale: range 0–100
Dimensions: mobility, self-care, usual activities, pain/discomfort,
anxiety/depression and cognition (6 items)
X X X Range 1–3 for each dimension.
*primary outcome
1only in the intervention group
Abbreviations: T0 baseline measurement, T1-T3 measurement after each treatment and T4-T8 follow up, T9 final measure, EORTC QLQ-C30 European organization
for research and treatment of cancer, quality of life questionnaire, QLQ-BR23 quality of life- breast cancer, DT distress thermometer, HADS hospital anxiety and
depression scale, IES impact of event scale, ICQ illness cognition questionnaire, EQ-6D euroQol-6D
Ploos van Amstel et al. BMC Cancer  (2016) 16:520 Page 6 of 9
the validity of these data, for 10 % of the data double
entry of data will be done. A statistician will check data
value ranges. All source data will be stored for 15 years.
Power calculations
Based on prior clinical studies [34] a difference of 10
points in the EORTC QLQ-C30 and its subscales is con-
sidered a clinically relevant difference for patients with
cancer. The power of the study to detect an effect of 10
points or more is calculated as follows.
The primary outcome is the global quality of life sub-
scale of the EORTC QLQ-C30 (sd = 22.7) at the end of
the study [43]. However, we aim for sufficient power for
the most important secondary outcomes – the subscales:
role function, emotional function, cognitive function and
social function of the EORTC QLQ-C30 (clinically rele-
vant difference 10 and sd = 18.7 – 22.8) [43]. Therefore,
we are aiming for 84 patients per group. The power of
the primary outcome then becomes more than 96 %,
and for the relevant subscales at least 80 %, when ana-
lyzing these outcomes with adjustment for baseline (i.e.,
an ANCOVA which has as much power as the t-test or
more depending on the correlation of the baseline meas-
urement with the measurement at the end of the trial).
Taking a drop-out of at most 15 % into account, a total
number of 193 patients needs to be included to have suffi-
cient power for the primary and secondary outcomes.
Statistical analysis
The primary analysis is the comparison of the primary
outcome global quality of life subscale of the EORTC
QLQ-C30 as measured at the end of the research period
analyzed by ANCOVA, i.e., an adjustment for baseline will
be included. The secondary analysis of the primary out-
come is a repeated measurements analysis of the sequence
of the repeated measurements in order to compare the
trends between the two groups (mixed model for repeated
measurements). Similar analysis will be carried out on the
secondary outcomes. Subgroup analysis will be performed
on demographic and treatment characteristics.
Missing data will be analyzed with the last observa-
tion carried forward method for the ANCOVA and a
sensitivity analysis assuming missing data to be missing-
at-random will be performed using a mixed model for
repeated measurements. Patients who have died, had
recurrence or metastasis of the breast cancer, or were
diagnosed with another malignancy during the study will
be considered to have dropped out of the study from that
event onwards.
Discussion
This study will evaluate the effect of an oncology
nurse-led DT intervention compared to usual care on
improving the quality of life of patients who are treated
for breast cancer with curative intent. The results will
contribute to the actual knowledge and the current dis-
cussion about using the DT in daily oncology practice
[25-27], as most previous studies were performed for
validation of the DT. Even though Hollingworth et al.
performed an RCT to measure the efficacy of the DT,
they used the DT once [24]. In our study, we will offer
a nurse-led DT intervention repeatedly in a period of
more than two years, which makes our study unique
and complementary to the existing literature. Despite a
natural recovery of quality of life over time, we will
expect additional improvement when using the DT
systematically during a longer period. As a primary
endpoint, we will use the EORTC QLQ-C30 global
quality of life scale. In order to compensate for prob-
able response shift, we will also inspect the secondary
outcomes to measure distress reduction. Additionally,
the results of this study will give us insight into the tra-
jectories of distress and quality of life from diagnosis to
2-year follow up in the usual care group. The short-
and long-term problems of patients with breast cancer
will become apparent. Therefore, the outcome of our
study may have impact on the future implementation of
the DT both nationally and internationally. The strengths
of our study are: (1) we will follow the guideline about dis-
tress management, (2) we will systematically assess and
discuss the DT for approximately 2 years follow up,
(3) we will discuss the DT results of all patients in
the intervention group with high distress in a psycho-
social MDT.
Conclusion
In conclusion, the aim of our study is to determine the
effectiveness of the systematic use of the DT and the
subsequent discussion of the results with a trained on-
cology nurse compared with usual care on the quality of
life of the patient with breast cancer. It is anticipated
that the results of the study will have impact on the fu-
ture implementation and standardization of the use of
the DT as part of routine care. It is expected that the
data collection will be completed early 2016.
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